Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification - Ou, S H; Kwak, E L; Siwak-Tapp, C (J Thorac Oncol, 2011)
, et al.